News Sentiment

PGEN sentiment intelligence

Precigen Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 61 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 4.95 Week of 17 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

80/100 classification confidence.

Company focus 52

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

-7.0% over one week, +2.7% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4

Market Reaction

Price moving ahead of tone

63/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 80/100 classification
One-week reaction -7.0% Price reacting lower
Trend fit Trend active 2.7% over four weeks
Fair value 121.7% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 22
Neutral 33
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 52
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 18
Stock Titan 8
TradingView 5
simplywall.st 5
Simply Wall Street 4
The Globe and Mail 2
Finviz 2
MT Newswires 2

Event Lens

What the news is about

Classified themes
Market update 34
Earnings 23
Regulatory and legal 3
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 61
GuruFocus Direct company coverage

Precigen (PGEN) to Release Q2 Financial Results and Discuss Business Progress

Precigen (PGEN) will announce its Q2 financial results on August 4, 2026, and hold a conference call to discuss business developments, including the recent FDA approval of PAPZIMEOS. The company reported a significant revenue increase in Q1 2026 due to PAPZIMEOS sales, leading to

Tone
Positive 63/100
Event
Earnings
Published
21 Jul 2026 16:40
Source
GuruFocus
Stock Titan Direct company coverage

Precigen sets 4:30 p.m. ET call for Aug. 4 business update

Precigen (Nasdaq: PGEN) announced it will release its second quarter 2026 financial results and provide business updates on Tuesday, August 4, 2026. A conference call to discuss the results will be held at 4:30 PM ET, and details are available on the company’s investor website. T

Tone
Neutral 50/100
Event
Earnings
Published
21 Jul 2026 11:40
Source
Stock Titan
TradingView Direct company coverage

ETFs Investing in Precigen Inc Stocks

This article provides a list of Exchange Traded Funds (ETFs) that hold shares of Precigen Inc. (PGEN), detailing each fund's market value, Precigen Inc. stock weight, issuer, management style, focus, expense ratio, AUM, price, change, and 3-year NAV total return. The ETFs cover v

Tone
Neutral 50/100
Event
Market update
Published
16 Jul 2026 23:09
Source
TradingView
Quartr Direct company coverage

Precigen (PGEN) Proxy Filing Summary

Precigen's upcoming annual meeting on June 26, 2025, will address director elections, an increase in authorized common stock, approval of Series A Preferred Stock and Warrants issuance to Randal J. Kirk, auditor ratification, executive compensation, and amendments to equity incen

Tone
Neutral 50/100
Event
Regulatory and legal
Published
16 Jul 2026 08:41
Source
Quartr
The Globe and Mail Direct company coverage

What Does the Sale of Precigen Shares Worth $1.1 Million by the CFO Mean for Investors?

Precigen CFO Harry Thomasian Jr. sold 200,000 shares for $1.1 million, reducing his direct ownership by 36% through a pre-arranged Rule 10b5-1 trading plan. This sale, occurring when shares hit a multi-year high, is not considered a red flag for investors due to the non-discretio

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 22:40
Source
The Globe and Mail
Simply Wall Street Direct company coverage

Precigen (PGEN) In Focus As Russell Removal Tests Its Undervalued Narrative

Precigen (PGEN) has been removed from several Russell indexes, which could impact its trading volumes and pricing despite strong recent stock performance. The company's stock is currently considered 55.3% undervalued by analysts, with a fair value estimate of $12.45, largely driv

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 19:43
Source
Simply Wall Street
Finviz Direct company coverage

PGEN - Precigen Inc Options

This article provides a detailed financial overview of Precigen Inc (PGEN), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators, such as EPS, sales growth, insider and institutional ownersh

Tone
Positive 62/100
Event
Earnings
Published
03 Jul 2026 12:39
Source
Finviz
Stock Titan Direct company coverage

[144] PRECIGEN, INC. SEC Filing

This article announces an SEC Form 144 filing by Precigen, Inc. (PGEN), detailing a proposed sale of securities. The filing indicates a sale of 346,836 shares of common stock with an aggregate market value of $2,044,627.16 by an individual named Smithfield, acquired through a sto

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 07:11
Source
Stock Titan
Moomoo Direct company coverage

Precigen Insider Sold Shares Worth $1,113,143, According to a Recent SEC Filing

A recent SEC filing revealed that an insider at Precigen sold shares totaling $1,113,143. This information is derived from the latest regulatory disclosure, indicating a significant insider transaction for the company.

Tone
Negative 29/100
Event
Regulatory and legal
Published
02 Jul 2026 17:40
Source
Moomoo
Finviz Direct company coverage

PGEN - Precigen Inc Latest SEC Filings

This article provides the latest SEC filings for Precigen Inc (PGEN), including key financial metrics, stock performance data, and insider/institutional ownership percentages. It details current market capitalization, income, sales, EPS, and various valuation ratios, alongside re

Tone
Neutral 50/100
Event
Earnings
Published
02 Jul 2026 04:40
Source
Finviz
Stock Titan Direct company coverage

[Form 4] PRECIGEN, INC. Insider Trading Activity

PRECIGEN, INC.'s President and CEO, Helen Sabzevari, conducted an exercise-and-sale transaction on June 29, 2026. She acquired 346,836 shares through stock options at $2.33 per share and subsequently sold them in open-market transactions at a weighted average price of $5.89, unde

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 04:34
Source
Stock Titan
Stock Titan Direct company coverage

Precigen (PGEN) COO sells 42,924 shares after option exercise

Precigen's Chief Operating Officer, Rutul R. Shah, exercised stock options to acquire 42,924 shares at $2.33 per share and subsequently sold all those shares in an open-market transaction at $5.85 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 22:40
Source
Stock Titan
Stock Titan Direct company coverage

Precigen (PGEN) CFO executes 200,000-share open-market sale under 10b5-1 plan

Precigen's Chief Financial Officer, Harry Thomasian Jr., sold a total of 200,000 shares of Common Stock in open-market transactions on June 29 and July 1, 2026, under a pre-arranged 10b5-1 trading plan. The sales were executed at weighted average prices of $5.78 and $5.53 per sha

Tone
Negative 32/100
Event
Market update
Published
01 Jul 2026 22:40
Source
Stock Titan
Simply Wall Street Direct company coverage

Does Precigen’s (PGEN) Russell Value Index Exit Signal a Shifting Investor Base or Story?

Precigen (PGEN) was removed from several Russell value indexes on June 27, 2026, which may lead to portfolio rebalancing by passive funds and shift its investor base towards more active investors. The company's investment narrative centers on the success of PAPZIMEOS and its abil

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 17:10
Source
Simply Wall Street
www.marketscreener.com Direct company coverage

Precigen, Inc.(NasdaqGS: PGEN) dropped from Russell 2000 Value Benchmark

Precigen, Inc. (PGEN) has been removed from the Russell 2000 Value Benchmark. This news follows a series of recent updates for the biopharmaceutical company, including winning FDA Orphan Drug Exclusivity for an airway disease treatment and reporting Q1 2026 earnings. The company,

Tone
Negative 40/100
Event
Earnings
Published
29 Jun 2026 15:05
Source
www.marketscreener.com
TradingView Direct company coverage

Precigen Inc Actuals & Estimates (BX:I5X)

This article provides an overview of Precigen Inc (BX:I5X) financial actuals and estimates, including income statement, balance sheet, and cash flow data, along with analyst forecasts. It covers key financial metrics such as market capitalization, earnings per share, revenue, net

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 16:39
Source
TradingView
The Globe and Mail Direct company coverage

Precigen Shareholders Expand Incentive Plan, Reaffirm Governance

Precigen shareholders approved an amendment to the company's 2023 Omnibus Incentive Plan, adding 7 million shares for equity awards, signaling continued support for equity-based compensation. They also re-elected directors, ratified auditors, and supported executive pay, reaffirm

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 03:41
Source
The Globe and Mail
TradingView Direct company coverage

Price to sales forward of Precigen, Inc. – NASDAQ:PGEN

This article provides a financial data point for Precigen, Inc. (NASDAQ: PGEN), specifically its forward price-to-sales ratio. The page indicates that the market is currently closed, and no trades have been executed. It appears to be a data-only page from TradingView, offering a

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 23:41
Source
TradingView
Stock Titan Direct company coverage

Precigen (PGEN) investors back 7M-share incentive pool and all board picks

Precigen, Inc. stockholders approved an amendment to the 2023 Omnibus Incentive Plan, increasing available shares for equity awards by 7 million. They also re-elected nine directors, ratified Deloitte & Touche LLP as the independent auditor for 2026, and passed a non-binding advi

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 20:11
Source
Stock Titan
Simply Wall Street Direct company coverage

Clearfield And 2 Insider Picks For Strong Growth

This article identifies three U.S. growth companies with high insider ownership: Clearfield (CLFD), BillionToOne (BLLN), and Precigen (PGEN). The U.S. market has seen a 2.3% decline recently, but is up 21% over the past year with 19% annual earnings growth forecasted. The article

Tone
Positive 64/100
Event
Earnings
Published
24 Jun 2026 11:10
Source
Simply Wall Street
Sahm Direct company coverage

Precigen (PGEN) Is Up 12.1% After Orphan Exclusivity Win for PAPZIMEOS Therapy - What's Changed

Precigen (PGEN) shares rose 12.1% following its PAPZIMEOS therapy receiving FDA orphan drug exclusivity, granting seven years of market protection for adult recurrent respiratory papillomatosis. This exclusivity strengthens the therapy's market position, especially with data show

Tone
Positive 67/100
Event
Market update
Published
24 Jun 2026 07:11
Source
Sahm
Simply Wall Street Direct company coverage

Precigen (PGEN) Stock Could Be 79% Undervalued After FDA Exclusivity Win

Precigen (PGEN) stock is under scrutiny after the FDA granted orphan drug exclusivity for PAPZIMEOS, which could significantly impact its commercial runway. Despite a strong recent share price performance, its high price-to-book ratio suggests it's overvalued based on current ass

Tone
Positive 67/100
Event
Market update
Published
22 Jun 2026 00:39
Source
Simply Wall Street
Market source Direct company coverage

Precigen (PGEN) Secures FDA Orphan Drug Exclusivity for PAPZIMEOS

Precigen (PGEN) obtained FDA orphan drug exclusivity for PAPZIMEOS, a precision medicine for adult recurrent respiratory papillomatosis (RRP), safeguarding its market exclusivity until August 2032. Developed with the AdenoVerse platform, PAPZIMEOS targets HPV 6 and 11, the causes

Tone
Positive 72/100
Event
Market update
Published
20 Jun 2026 19:40
Source
Market source
TradingView Direct company coverage

PGEN: All proposals, including board elections and compensation, passed overwhelmingly without shareholder questions

Precigen, Inc. (PGEN) held its 2026 AGM where all proposals, including board elections, auditor ratification, executive compensation, and an incentive plan amendment, passed with overwhelming support. There were no shareholder questions or comments received during the meeting. Th

Tone
Positive 70/100
Event
Market update
Published
18 Jun 2026 13:40
Source
TradingView
TradingKey Direct company coverage

Precigen Inc (PGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates

Precigen Inc (PGEN) has an earnings forecast score of 7.33, placing it 103rd out of 157 in the Pharmaceuticals industry. Analysts have set an average price target of $8.50 for PGEN, with a "Buy" trend based on ratings from 3 analysts. The company's expected revenue for the next q

Tone
Positive 66/100
Event
Earnings
Published
18 Jun 2026 10:40
Source
TradingKey